Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients who were prescribed with palbociclib in combination with AI for at least 1 cycle during the index period
Patients who were diagnosed with BC during the index period
You may not be if
Male
Prescribed with palbociclib during 12-month period preceding the index date
Clareo Health | Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
